Author:
Kusamura Shigeki,Delhorme Jean-Baptiste,Taibi Abdelkader,Villeneuve Laurent,Deraco Marcello,Dico Rea Lo,Glehen Olivier,Moran Brendan
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.
2. Pietrantonio F, Maggi C, Fanetti G, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist. 2014;19:845–50.
3. Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99:591–6.
4. Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an a-lysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837–41.
5. Carr N, Sobin L. Tumors of the appendix. In: Bosman FT, Carneiro F, Hruban RH, et al. editors. WHO Classification of tumours of the digestive system. World Health Organization classification of tumours, vol. 3, ed. 4. Lyon: IARC Press; 2010. p 122–5.